Clinerion enters Asia through strategic alliance with ASUS Life

By Melissa Fassbender contact

- Last updated on GMT

Clinerion enters Asia through strategic alliance with ASUS Life

Related tags: Clinical research services, Clinical trial

The alliance expands the geographic reach of sponsors, giving customers real-time, EHR-based insight on the Taiwanese patient population.

The alliance between Clinerion and ASUS Life looks to accelerate drug development and was signed today at the HIMSS 17 conference in Orland, Florida.

ASUS Life is a joint venture that combines ASUS’ information technology with the clinical research services of the Show Chwan Healthcare System, in Taiwan.

The new alliance expands the geographic reach of sponsors seeking cohorts relevant to their clinical trials​,” Ulf Claesson, Clinerion CEO, told us.

According to the company, trial staff will be able to recruit eligible patients at Show Chwan’s eight hospital sites using Clinerion’s Patient Recruitment System (PRS).

Due to its live, EHR-based integration with partner hospitals, Clinerion’s PRS can find patients “much more rigorously than through traditional means​,” explained Claesson. “This means 10 to 30 times more patients foundand finding them in minutes rather than days, or weeks.​”

For CROs, he said Clinerion’s PRS provides a new tool for clinical trial management, enabling them to support trial sponsors “more efficiently and effectively​.”

The collaboration also enables patient matching with medications for rare and orphan diseases and real-world data generation for evidence analyses.

Patient data technology in Asia

When it comes to patient data technology, Asia is already at a good level​,” Claesson, explained. “As all over the globe quality differs from country to country and hospital to hospital, but in general the quality and consistency of digital patient data are excellent​.”

Claesson said Taiwan is at the forefront – which was why he explained the partnership with ASUS was a good fit.

What is still missing is technology that can network them to the rest of the world and make their hospitals stand out when trial siting decisions are made​,” he added. “This is where Clinerion comes i​n.”

The company has plans to expand coverage in key geographies, such as Korea, Japan, China, and Singapore.

Expect to hear more from Clinerion on this topic,​” Claesson said.

(Feature image: iStock/bedo)

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars